Medication Management in CYP2D6 Poor Metabolizers

Introduction to CYP2D6 Poor Metabolizers

CYP2D6 is a key enzyme in the cytochrome P450 system that metabolizes approximately 25% of clinically used medications, with poor metabolizers having no functional CYP2D6 enzyme activity due to genetic variants, affecting about 5-10% of Caucasians and less than 1% of Asian populations 1, 2
CYP2D6 poor metabolizers require medication dose adjustments, alternative medication selections, and careful monitoring to prevent adverse effects due to elevated drug concentrations of medications metabolized by this enzyme 1, 2

The American Heart Association recommends careful dosing of flecainide and propafenone in poor metabolizers, as they show increased plasma concentrations and enhanced effects 3
The American College of Clinical Pharmacology suggests that risperidone should be used with caution in poor metabolizers, as it is associated with 3.4 times higher odds of moderate-to-marked adverse drug reactions and 6.0 times higher odds of discontinuation due to adverse effects 3
The National Institute of Mental Health recommends citalopram, escitalopram, and sertraline over fluoxetine and paroxetine in poor metabolizers, as they are less dependent on CYP2D6 3
The FDA recommends that nebivolol does not require dose adjustments for patients who are CYP2D6 poor metabolizers, as clinical effects and safety profiles were similar to extensive metabolizers 3
SSRIs and SNRIs, such as fluoxetine and paroxetine, can result in 3-4 fold higher drug concentrations in poor metabolizers, increasing the risk of adverse effects 2
Antipsychotics, which are CYP2D6 substrates, may reach toxic levels in poor metabolizers, resulting in a higher risk of extrapyramidal symptoms and other adverse effects 2
Beta-blockers, especially metoprolol, show increased plasma concentrations and enhanced effects in poor metabolizers, increasing the risk of bradycardia and hypotension 4

The Clinical Pharmacogenetics Implementation Consortium recommends starting with 25-50% of standard doses for CYP2D6 substrates and titrating slowly based on clinical response and side effects, to prevent adverse effects due to elevated drug concentrations 3
The European Society of Clinical Pharmacology suggests monitoring closely for side effects, including serotonin syndrome, QT prolongation, and anticholinergic effects, and checking drug levels when available, to ensure safe and effective medication use in poor metabolizers 3
Start with lower doses (25-50% of standard) for CYP2D6 substrates, and consider alternative antidepressants less dependent on CYP2D6, such as citalopram, escitalopram, and sertraline 4
Monitor drug levels when available, and titrate slowly based on clinical response and side effects 4

The American College of Clinical Pharmacology recommends choosing medications that are not metabolized by CYP2D6 when possible, such as morphine, oxycodone, or hydromorphone for pain management, to avoid reduced efficacy or increased risk of adverse effects 3
The National Comprehensive Cancer Network suggests considering alternative hormonal therapy or higher tamoxifen dose in poor metabolizers, as they have reduced efficacy due to lower conversion to active metabolite (endoxifen) 3
Avoid codeine in poor metabolizers due to lack of efficacy, and use alternative analgesics not dependent on CYP2D6 activation, such as morphine, oxycodone, and hydromorphone 5
Tamoxifen poor metabolizers have reduced tamoxifen efficacy due to lower endoxifen levels, and may require alternative hormonal therapy or higher tamoxifen dose 4, 6

The Clinical Pharmacogenetics Implementation Consortium recommends CYP2D6 genotyping as valuable before initiating medications with narrow therapeutic indices, to guide medication selection and dosing and reduce the risk of adverse effects 3
Consider CYP2D6 genotyping before initiating medications with narrow therapeutic indices that are CYP2D6 substrates, and testing is particularly valuable for medications where efficacy depends on metabolic activation or toxicity is a concern 6
Prevent "phenocopying" by avoiding CYP2D6 inhibitors that can convert normal metabolizers into functional poor metabolizers, and be cautious with polypharmacy involving multiple CYP2D6 substrates 4, 6

Inform patients about their metabolizer status and its implications, and advise about potential side effects and when to seek medical attention 6
Encourage reporting unusual responses to medications, and monitor closely for side effects, including serotonin syndrome, QT prolongation, and anticholinergic effects 4
Start with lower doses and titrate slowly based on clinical response and side effects, and monitor drug levels when available 4